Company intelligence / Profile preview
Attralus
San Francisco/Burlingame/South San Francisco*, California, United Statesattralus.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Attralus has demonstrated promising preclinical results with its PAR therapeutic AT‑02 showing significant reduction of amyloid burden in animal models. Early clinical data from imaging agent AT‑01 show detection of multiple types of systemic amyloidosis. The company’s lead therapeutic candidate AT‑02 is currently being evaluated in a Phase 1/2 trial for AL and ATTR amyloidosis patients. Imaging agent Iodine (^124I) evuzamitide has reached Phase 3 development for cardiac amyloidosis diagnosis.
- Therapeutic areas
- NeurologyRare DiseasesCardiovascular
- Modalities
- Monoclonal antibodies (mAbs)Fusion proteins (e.g., IgG1 fusion)Diagnostic radiopharmaceuticals (imaging agents)Peptide-based therapeutics
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Bristol Myers Squibb participated as an investorUniversity of Tennessee Research Foundation and University of Limoges provide licensing agreements for key technologies.
Beyond the preview
Go deeper on Attralus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Attralus.